Trump Administration Delays Billions in HHS Grants Over Political Review Process

The Trump administration has implemented a new political review process that is holding up billions of dollars in congressionally approved health funding, creating unprecedented delays for programs addressing the nation's ongoing addiction crisis, suicide prevention efforts, and disease outbreak preparedness.

Internal documents, public records, and interviews with more than a dozen current and former Health and Human Services employees reveal a multi-layered approval system that has brought the federal grant process to a standstill. The new regime requires all HHS funding opportunities to clear an AI screening that flags keywords the administration finds objectionable—including terms like "culture," "harm reduction," "gender," and "transgender"—before advancing to human review.

A Bottleneck at Every Level

Once the AI screening is complete, applications must pass through an HHS assistant secretary for financial review, then advance to Health Secretary Robert F. Kennedy Jr.'s office for approval. The final hurdle lies outside the department entirely: the White House Office of Management and Budget must sign off before any funding opportunity can proceed.

The results have been stark. States and health organizations are currently waiting on $211 million in grants to expand 988 suicide hotline capacity, $75 million to build global disease outbreak response capabilities, $3 million to establish opioid addiction treatment centers, and $95 million for programs designed to improve overall public health system performance. The list of delayed allocations stretches across virtually every corner of the department's portfolio.

The backlog has put critical public health infrastructure at risk at a moment when the nation has finally begun making progress against overdose deaths. After years of relentless increases, drug overdose mortality declined 14% nationally in 2025, marking the third consecutive year of improvement. Public health experts warn that disrupting funding flows now threatens to reverse hard-won gains.

Maryland Programs Caught in the Freeze

In Maryland, the new policy has complicated efforts to combat the opioid crisis at the community level. Organizations that had come to rely on federal support for overdose prevention, medication-assisted treatment expansion, and harm reduction services now face uncertainty about when—or whether—promised funding will materialize.

The policy does contain one notable loophole: federal funds can still be used for test strips for law enforcement, EMTs, public health officials, and other health professionals. This creates an important channel for government agencies that test drugs and issue reports on adulterants saturating the drug supply in specific locations. However, medical experts note that this exception does not extend to the community-based distribution of test strips that has proven effective at changing behavior among people who use drugs.

Dr. Yngvild Olsen, who oversaw SAMHSA's Center for Substance Abuse Treatment under both the Biden and Trump administrations, points to substantial evidence that giving test strips directly to people who use drugs can change behavior and reduce overdose risk. The administration's distinction between professional testing and community distribution reflects a philosophical divide over whether harm reduction tools should be deployed directly to active drug users.

The AI Screening Layer

The artificial intelligence screening that now sits at the front of the grant approval process represents a novel approach to federal funding oversight. By training algorithms to flag specific terminology, the administration has created an automated filter that catches applications before they ever reach human reviewers.

The flagged terms extend beyond the politically charged vocabulary of gender and culture. "Harm reduction"—a public health framework that emphasizes practical strategies to reduce negative consequences associated with drug use—has become a particular target. This approach has drawn criticism from addiction medicine specialists who note that harm reduction strategies like naloxone distribution and medication-assisted treatment have contributed significantly to recent mortality declines.

The screening process adds a layer of delay to a grant system that was already notorious for its sluggishness. Federal health grants have traditionally moved slowly, with months often passing between application submission and funding decisions. The new approval requirements have extended these timelines substantially, leaving organizations in limbo and forcing some to consider scaling back services.

Political Oversight of Scientific Funding

The requirement for White House Office of Management and Budget approval of all HHS funding opportunities represents a significant centralization of control over federal health spending. Historically, grant programs have operated with considerable autonomy within their statutory mandates, with political appointees at the departmental level exercising oversight.

The new system places ultimate approval authority in the White House, effectively subjecting all federal health funding to direct political review. This arrangement has raised concerns about whether funding decisions will be driven by scientific merit and programmatic need or by alignment with administration priorities.

HHS spokespersons have defended the process, stating that all grant funding opportunities "follow the standard review and approval process" and that the department will release remaining notices of funding opportunities for Fiscal Year 2026 once finalized. However, the spokesperson did not address questions about the duration of delays or the specific criteria being applied at each review layer.

Impact on the Ground

For organizations operating addiction treatment programs, suicide prevention hotlines, and disease surveillance systems, the funding delays have created immediate operational challenges. Many federal grants support multi-year programs with established staffing and service commitments. When funding announcements are delayed, organizations must either draw down reserves, reduce services, or risk breaking commitments to the communities they serve.

The $211 million in suspended 988 suicide hotline funding is particularly consequential. The national suicide prevention lifeline, which transitioned to the three-digit dialing code in 2022, has struggled with capacity constraints since its launch. The delayed grants were intended to expand crisis center operations and improve answer rates, which have lagged targets in many jurisdictions.

Similarly, the $3 million in delayed opioid treatment center funding comes at a moment when communities are attempting to build out infrastructure to serve populations with substance use disorders. Despite recent mortality declines, approximately 70,000 Americans still die from drug overdoses annually, and treatment capacity remains inadequate to meet demand.

Questions of Sustainability

The funding delays raise broader questions about the sustainability of public health progress achieved over the past three years. The 14% national decline in overdose deaths has been attributed to a combination of expanded naloxone distribution, increased access to medication-assisted treatment, and the proliferation of harm reduction services.

Many of these interventions rely on federal funding flows that are now subject to the new approval process. If grants continue to be delayed or if funding priorities shift under political review, the infrastructure that has supported mortality reductions could begin to erode.

The administration has simultaneously pursued other policy changes affecting addiction treatment, including a SAMHSA guidance document cautioning against indefinite medication-assisted treatment and the elimination of federal funding for fentanyl test strips. Taken together, these moves suggest a philosophical shift away from harm reduction approaches and toward models emphasizing abstinence and recovery.

Whether this shift will affect the trajectory of overdose mortality remains to be seen. What is clear is that the new grant approval process has introduced substantial uncertainty into the funding streams that support the nation's response to its most pressing public health challenges.